Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Canc ...
PDF (296 KB)
Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and ...
PDF (167 KB)
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Can ...
PDF (139 KB)
​​​​​​​New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutate ...
PDF (215 KB)
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastati ...
PDF (246 KB)
Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastati ...
PDF (256 KB)
Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer
PDF (155 KB)
Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organ ...
PDF (181 KB)
Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D
PDF (131 KB)
Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC ...
PDF (231 KB)
Showing 1 - 10 of 44 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...